This information is intended for media professionals and investors

Juvent’s History

Juvent’s patented Dynamic Motion Therapy® technology was originally known as Mechanical Stress Technology (MST). This technology was developed at the State University of New York at Stony Brook (SUNY SB) during the late 1980s and early 1990s.

In 1993, legendary medical device developer, Jack Ryaby, along with Drs. Rubin and McLeod joined forces to form a venture company called Exogen to develop and commercialize MST, as well as a related ultrasound technology. Between 1993 and 1999, development of MST continued through animal research studies on the effect of small mechanical forces on bone formation, including a study funded by NASA to assess MST as a potential remedy for the significant bone loss that occurs during extended space missions. Exogen also conducted a large clinical study that demonstrated a significant effect in preventing bone loss in post-menopausal women, confirming the opportunity for MST to be the first non-drug treatment for osteopenia and osteoporosis.

Exogen realized a successful public offering in 1995 and was later acquired by Smith and Nephew, Inc. (S&N) in the fall of 1999. S&N initially planned a major clinical trial of MST, but decided to spin off the technology following a major re-organization that focused the company on trauma and reconstructive surgery. Jack Ryaby thought so much of the MST technology that in 2003 he purchased the rights from S&N and formed a new venture company, JUVENT Medical Corporation, Inc. (JMC). Over the next six years, JMC invested millions to complete a large, prospective, randomized and controlled trial; secure numerous patents; produce the first commercial device (the Juvent 1000); receive CE and international approval for the treatment of osteoporosis; and build an international sales and distribution network. The company succeeded in developing a revolutionary product and a strong brand, but after only a year, Jack Ryaby, founding CEO and visionary, died of congestive heart failure. New, less experienced management made numerous operational and strategic mistakes. Plagued by overseas manufacturing delays, and overspending on occupancy and personnel, JMC was unable to endure the economic downturn of 2008 and filed for bankruptcy in July 2009. American Medical Innovations, Inc. (AMI) purchased the Juvent IP portfolio out of bankruptcy in July 2009. American Medical Innovations, Inc. (AMI) purchased the Juvent IP portfolio out of bankruptcy. AMI’s principal, a successful Juvent patient with a doctorate in education and little business experience unsuccessfully attempted to re-launch the Juvent 1000. Regenerative Technologies Corporation (RTC) was formed in 2011 to acquire this technology from AMI and re-launch the Juvent platform in the marketplace.

Photos and interviews with company personnel are available upon request by contacting Rush Simonson - rush.simonson@juvent.com

Juvent - Regenerative Technologie Corporation - 04/2016